TMCnet News
Heru, Inc., A 3 Seasons Capital, LLC Portfolio Medical Technology Company, Receives Class 1 Listing With the FDA for Developing a Next-Generation, Artificial Intelligence (AI)-Driven Platform for Vision Diagnostics and Augmentation
[December 28, 2020]
Heru, Inc., A 3 Seasons Capital, LLC Portfolio Medical Technology Company, Receives Class 1 Listing With the FDA for Developing a Next-Generation, Artificial Intelligence (AI)-Driven Platform for Vision Diagnostics and Augmentation
MIAMI, Dec. 28, 2020 /PRNewswire/
 Heru, Inc., a 3 Seasons Capital, LLC portfolio medical technology company, has received Class 1 listing with the U.S. Food and Drug Administration (FDA) registration for developing a next-generation, artificial intelligence (AI)-driven platform for vision diagnostics and augmentation. Heru is the first diagnostic application for visual field exams.
Medical Technology Company Heru, Inc. Completes FDA Registration Following a $2.7M Seed Round
By
Staff
3 months ago
Heru, Inc. comes out of stealth mode to announce the development of a novel artificial intelligence (AI) driven vision diagnostic and augmentation platform
Heru’s technology registered with the FDA for its ground-breaking AI-powered visual field test using augmented reality
Originating as a spinout from Bascom Palmer Eye Institute, ranked number one in ophthalmology and recognized as a global leader in vision research, medical education, and patient care
Industry veteran John Trefethen joins Heru’s leadership team as Chief Marketing Officer
Funding round led by Maurice R. Ferre, MD, Fred H. Moll, MD and a syndicate of seasoned technology veterans